glp 1 in heart failure Vascular and metabolic effects of SGLT2i and GLP-1 patients | Heart Failure Reviews of the evidence supporting the

Warnings and Precautions Hypokalemia: B12 therapy may cause a drop in potassium levels (hypokalemia), particularly during early treatment in patients with significant B12 deficiency

I mean, what are we doing here

SGLT2, GLP-1 RA Combination Therapy Improves Cardiovascular, Kidney Outcomes in Diabetes Findings from a recent study are providing support for the combined use of sodium-glucose transport protein 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists to optimize cardiovascular and kidney outcomes The collaborative meta-analysis Given the rapidly expanding indications for the use of GLP-1 receptor agonists, it was important to look at their effects with SGLT2 inhibitors, said Brendon L Neuen , MBBS, PhD, nephrologist and director of the Kidney Trials Unit at Royal North Shore Hospital and senior research fellow at The George Institute for Global Health , in a press release

Nature Reviews Endocrinology, 8, 728-42

This is consistent with the evidence of pulmonary fibrosis observed in humans and animal models after exposure to PHMG (Kim et al., 2021